{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:59:57Z","timestamp":1790459997433,"version":"4.1.0"},"reference-count":187,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.bcmd.2017.12.001","type":"journal-article","created":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T20:14:49Z","timestamp":1514924089000},"page":"87-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Gene therapy and gene editing strategies for hemoglobinopathies"],"prefix":"10.1016","volume":"70","author":[{"given":"Maria Rosa","family":"Lidonnici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0790-3133","authenticated-orcid":false,"given":"Giuliana","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2017.12.001_bb0005","first-page":"51","article-title":"Molecular biology of hemoglobin: its application to sickle cell anemia and thalassemia","volume":"43","author":"Kan","year":"1991","journal-title":"Schweiz. Med. Wochenschr. Suppl."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0010","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2471\/BLT.06.036673","article-title":"Global epidemiology of haemoglobin disorders and derived service indicators","volume":"86","author":"Modell","year":"2008","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0015","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(12)61229-X","article-title":"Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates","volume":"381","author":"Piel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0020","series-title":"Expert Panel Report","article-title":"Evidence-based management of sickle cell disease","author":"National Heart, Lung, Blood Institute","year":"2014"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0025","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/0006-3002(59)90183-0","article-title":"Abnormal human haemoglobins. III. The chemical difference between normal and sickle cell haemoglobins","volume":"36","author":"Ingram","year":"1959","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0030","series-title":"Anemias and Other Red Cell Disorders","author":"Bridges","year":"2008"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0035","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1182\/blood.V68.5.985.985","article-title":"Alpha-thalassemia in blacks: genetic and clinical aspects and interactions with the sickle hemoglobin gene","volume":"68","author":"Steinberg","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0040","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMct0708272","article-title":"Hydroxyurea for the treatment of sickle cell anemia","volume":"358","author":"Platt","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0045","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.ijbiomac.2016.09.073","article-title":"Sickle cell disease: its molecular mechanism and the one drug that treats it","volume":"93","author":"Ferrone","year":"2016","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399406010659","article-title":"Pathophysiology and therapy for haemoglobinopathies. Part I: sickle cell disease","volume":"8","author":"Madigan","year":"2006","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0055","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/ajh.20402","article-title":"Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia","volume":"80","author":"Vichinsky","year":"2005","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0060","first-page":"704","article-title":"Inherited haemoglobin disorders: an increasing global health problem","volume":"79","author":"Weatherall","year":"2001","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0065","article-title":"Thalassaemia","author":"Taher","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0070","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3324\/haematol.2013.099747","article-title":"Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel","volume":"99","author":"Angelucci","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0075","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/bmt.2015.293","article-title":"Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000\u20132010","volume":"51","author":"Baronciani","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0080","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","article-title":"Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation","volume":"129","author":"Gluckman","year":"2017","journal-title":"Blood"},{"issue":"1017","key":"10.1016\/j.bcmd.2017.12.001_bb0085","article-title":"Evolution of hemoglobin loci and their regulatory elements","volume":"S1079\u20139796","author":"H","year":"2017","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0090","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.278.5339.876","article-title":"Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease","volume":"278","author":"Paszty","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0095","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1002\/j.1460-2075.1991.tb04877.x","article-title":"Towards a transgenic mouse model of sickle cell disease: hemoglobin SAD","volume":"10","author":"Trudel","year":"1991","journal-title":"EMBO J."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0100","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/0092-8674(83)90562-7","article-title":"A mouse model for beta-thalassemia","volume":"34","author":"Skow","year":"1983","journal-title":"Cell"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0105","doi-asserted-by":"crossref","first-page":"11608","DOI":"10.1073\/pnas.92.25.11608","article-title":"A mouse model for beta 0-thalassemia","volume":"92","author":"Yang","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0110","first-page":"887","article-title":"Regulated expression of a complete human beta-globin gene encoded by a transmissible retrovirus vector","volume":"7","author":"Cone","year":"1987","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/331035a0","article-title":"Lineage-specific expression of a human beta-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells","volume":"331","author":"Dzierzak","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0120","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1073\/pnas.87.9.3386","article-title":"High-level beta-globin expression after retroviral transfer of locus activation region-containing human beta-globin gene derivatives into murine erythroleukemia cells","volume":"87","author":"Novak","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0125","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1073\/pnas.89.7.3107","article-title":"A 36-base-pair core sequence of locus control region enhances retrovirally transferred human beta-globin gene expression","volume":"89","author":"Chang","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0130","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1182\/blood.V81.5.1384.1384","article-title":"A human beta-globin gene fused to the human beta-globin locus control region is expressed at high levels in erythroid cells of mice engrafted with retrovirus-transduced hematopoietic stem cells","volume":"81","author":"Plavec","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0135","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0140","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/35017565","article-title":"Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin","volume":"406","author":"May","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0145","doi-asserted-by":"crossref","first-page":"14380","DOI":"10.1073\/pnas.212507099","article-title":"Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells","volume":"99","author":"Imren","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0150","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1182\/blood-2002-10-3305","article-title":"A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer","volume":"101","author":"Rivella","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0155","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1182\/blood-2004-03-0863","article-title":"Extended beta-globin locus control region elements promote consistent therapeutic expression of a gamma-globin lentiviral vector in murine beta-thalassemia","volume":"104","author":"Hanawa","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0160","doi-asserted-by":"crossref","first-page":"10547","DOI":"10.1073\/pnas.0711666105","article-title":"In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia","volume":"105","author":"Miccio","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032345","article-title":"Therapeutic hemoglobin levels after gene transfer in beta-thalassemia mice and in hematopoietic cells of beta-thalassemia and sickle cells disease patients","volume":"7","author":"Breda","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027955","article-title":"The GATA1-HS2 enhancer allows persistent and position-independent expression of a beta-globin transgene","volume":"6","author":"Miccio","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0175","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1182\/blood-2007-08-108647","article-title":"Locus control region elements HS1 and HS4 enhance the therapeutic efficacy of globin gene transfer in beta-thalassemic mice","volume":"110","author":"Lisowski","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0180","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1038\/sj.mt.6300259","article-title":"Improved human beta-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element","volume":"15","author":"Arumugam","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0185","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1089\/104303401753153947","article-title":"Systematic determination of the packaging limit of lentiviral vectors","volume":"12","author":"Kumar","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0190","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3324\/haematol.2010.031013","article-title":"Quantitatively different red cell\/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease","volume":"96","author":"Andreani","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0195","first-page":"298","article-title":"Gene therapy for hemoglobinopathies: are we there yet?","volume":"3","author":"Puthenveetil","year":"2004","journal-title":"Curr. Hematol. Rep."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0200","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/emmm.201000083","article-title":"Correction of beta-thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients","volume":"2","author":"Roselli","year":"2010","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0205","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/emmm.201000086","article-title":"Gaining the hard yard: pre-clinical evaluation of lentiviral-mediated gene therapy for the treatment of beta-thalassemia","volume":"2","author":"Milsom","year":"2010","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0210","doi-asserted-by":"crossref","first-page":"9852","DOI":"10.1073\/pnas.91.21.9852","article-title":"Recombinant human hemoglobins designed for gene therapy of sickle cell disease","volume":"91","author":"McCune","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0215","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1126\/science.1065806","article-title":"Correction of sickle cell disease in transgenic mouse models by gene therapy","volume":"294","author":"Pawliuk","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0220","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1182\/blood-2003-04-1251","article-title":"Correction of a mouse model of sickle cell disease: lentiviral\/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells","volume":"102","author":"Levasseur","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0225","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1172\/JCI67930","article-title":"Beta-globin gene transfer to human bone marrow for sickle cell disease","volume":"123","author":"Romero","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0230","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/mt.2008.259","article-title":"Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin","volume":"17","author":"Pestina","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0235","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood-2002-07-2211","article-title":"The degree of phenotypic correction of murine beta-thalassemia intermedia following lentiviral-mediated transfer of a human gamma-globin gene is influenced by chromosomal position effects and vector copy number","volume":"101","author":"Persons","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0240","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1182\/blood-2009-01-201863","article-title":"A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction","volume":"114","author":"Perumbeti","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0245","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/hgtb.2017.096","article-title":"A guide to approaching regulatory considerations for lentiviral-mediated gene therapies","volume":"28","author":"White","year":"2017","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0250","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1182\/blood-2002-01-0219","article-title":"Development of virus vectors for gene therapy of beta chain hemoglobinopathies: flanking with a chromatin insulator reduces gamma-globin gene silencing in vivo","volume":"100","author":"Emery","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0255","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1634\/stemcells.2008-0258","article-title":"Combinatorial incorporation of enhancer-blocking components of the chicken beta-globin 5'HS4 and human T-cell receptor alpha\/delta BEAD-1 insulators in self-inactivating retroviral vectors reduces their genotoxic potential","volume":"26","author":"Ramezani","year":"2008","journal-title":"Stem Cells"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005956","article-title":"Gene specificity of suppression of transgene-mediated insertional transcriptional activation by the chicken HS4 insulator","volume":"4","author":"Desprat","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0265","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature09328","article-title":"Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia","volume":"467","author":"Cavazzana-Calvo","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0270","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1172\/JCI61852","article-title":"Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts","volume":"122","author":"Moiani","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0275","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2174\/1566523214666141127095336","article-title":"Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of beta-thalassemia and sickle cell disease","volume":"15","author":"Negre","year":"2015","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0280","series-title":"The European Society for Gene and Cell Therapy and the Spanish Society for Gene and Cell Therapy Collaborative Congress 2013","first-page":"A109","article-title":"High dose of transduced HPSCs provides safe long term correction of beta-thalassemia","author":"Lidonnici","year":"2013"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0285","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.jcyt.2017.06.002","article-title":"Preclinical studies for a phase 1 clinical trial of autologous hematopoietic stem cell gene therapy for sickle cell disease","volume":"19","author":"Urbinati","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0290","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.hoc.2017.05.003","article-title":"Gene therapy approaches to immunodeficiency","volume":"31","author":"Ghosh","year":"2017","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0295","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.molmed.2016.02.002","article-title":"Treating immunodeficiency through HSC gene therapy","volume":"22","author":"Booth","year":"2016","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0300","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0305","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0310","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nm.2088","article-title":"Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease","volume":"16","author":"Stein","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0315","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007280","article-title":"Gene therapy for Wiskott-Aldrich syndrome\u2014long-term efficacy and genotoxicity","volume":"6","author":"Braun","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0320","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/mt.2011.166","article-title":"Retroviral gene therapy for X-linked chronic granulomatous disease: results from phase I\/II trial","volume":"19","author":"Kang","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0325","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.hoc.2017.06.006","article-title":"Historical perspective on the current renaissance for hematopoietic stem cell gene therapy","volume":"31","author":"Kohn","year":"2017","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0330","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.hoc.2017.06.010","article-title":"Gene therapy approaches to hemoglobinopathies","volume":"31","author":"Ferrari","year":"2017","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0335","series-title":"59th ASH Annual Meeting & Exposition","article-title":"Clinical outcomes up to 3 years following lentiglobin gene therapy for transfusion-dependent \u03b2-thalassemia in the Northstar Hgb-204 study","author":"Kwiatkowski","year":"2017"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0340","series-title":"58th ASH Annual Meeting & Exposition, Blood","first-page":"1175","article-title":"Lentiglobin gene therapy for transfusion-dependent \u03b2-thalassemia: update from the Northstar Hgb-204 phase 1\/2 clinical study","author":"Thompson","year":"2016"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0345","series-title":"58th ASH Annual Meeting & Exposition, Blood","first-page":"2311","article-title":"Update from the Hgb-205 phase 1\/2 clinical study of lentiglobin gene therapy: sustained clinical benefit in severe hemoglobinopathies","author":"Ribeil","year":"2016"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0350","series-title":"22th EHA","article-title":"Update on the first patients with severe hemoglobinopathies treated with lentiglobin gene therapy","author":"Ribeil","year":"2017"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0355","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/hum.2016.037","article-title":"Cell and gene therapy for the beta-thalassemias: advances and prospects","volume":"27","author":"Mansilla-Soto","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0360","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2012-04-423822","article-title":"Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan","volume":"120","author":"Bernardo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0365","series-title":"ASGCT's 20th Annual Meeting, Molecular Therapy","first-page":"331","article-title":"Gene therapy for beta thalassemia: initial results from TIGET BTHAL clinical trial","author":"Scaramuzza","year":"2017"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0370","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1182\/blood.V97.10.3313","article-title":"Fatal sickle cell crisis after granulocyte colony-stimulating factor administration","volume":"97","author":"Adler","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0375","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene therapy in a patient with sickle cell disease","volume":"376","author":"Ribeil","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0385","series-title":"58th ASH Annual Meeting & Exposition, Blood","first-page":"1176","article-title":"Interim results from a phase 1\/2 clinical study of lentiglobin gene therapy for severe sickle cell disease","author":"Kanter","year":"2016"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0390","series-title":"59th ASH Annual Meeting & Exposition","article-title":"Interim results from a phase 1\/2 clinical study of lentiglobin gene therapy for severe sickle cell disease","author":"Kanter","year":"2017"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0395","series-title":"59th ASH Annual Meeting & Exposition","article-title":"Successful plerixafor-mediated mobilization, apheresis, and lentiviral vector transduction of hematopoietic stem cells in patients with severe sickle cell disease","author":"Tisdale","year":"2017"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0400","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrd1134","article-title":"The bicyclam AMD3100 story","volume":"2","author":"De Clercq","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0405","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0410","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/mt.2011.195","article-title":"Hematopoietic stem cell mobilization for gene therapy of adult patients with severe beta-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects","volume":"20","author":"Yannaki","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0415","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1089\/hum.2013.163","article-title":"Hematopoietic stem cell mobilization for gene therapy: superior mobilization by the combination of granulocyte-colony stimulating factor plus plerixafor in patients with beta-thalassemia major","volume":"24","author":"Yannaki","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0420","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2015-03-629618","article-title":"Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy","volume":"126","author":"Karponi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0425","series-title":"ASGCT's 20th Annual Meeting, Molecular Therapy","first-page":"90","article-title":"Addition of dmPGE2 enhances BM and mPB CD34+ cell transduction preserving in vivo reconstitution potential, differentiation and integration profile of Globin-LV","author":"Lidonnici","year":"2017"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0430","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1080\/14653240902849788","article-title":"Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?","volume":"11","author":"Fitzhugh","year":"2009","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0435","series-title":"59th ASH Annual Meeting & Exposition","article-title":"Safety and efficacy trial of escalation of plerixafor for mobilization of CD34+ Hematopoietic Progenitor Cells (HPCs) for globin gene transfer in patients with sickle cell disease","author":"Boulad","year":"2017"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0440","doi-asserted-by":"crossref","first-page":"1233151","DOI":"10.1126\/science.1233151","article-title":"Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome","volume":"341","author":"Aiuti","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0445","doi-asserted-by":"crossref","first-page":"1233158","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0450","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.stem.2016.04.016","article-title":"In vivo tracking of human hematopoiesis reveals patterns of clonal dynamics during early and steady-state reconstitution phases","volume":"19","author":"Biasco","year":"2016","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0455","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/stem.1957","article-title":"Enrichment of human hematopoietic stem\/progenitor cells facilitates transduction for stem cell gene therapy","volume":"33","author":"Baldwin","year":"2015","journal-title":"Stem Cells"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0460","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1182\/blood.V91.12.4489","article-title":"Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma","volume":"91","author":"Tricot","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0465","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1083-8791(00)70008-5","article-title":"Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer","volume":"6","author":"Negrin","year":"2000","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0470","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S0301-472X(00)00169-7","article-title":"Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution","volume":"28","author":"Michallet","year":"2000","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0475","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.stemcr.2017.02.010","article-title":"Efficient ex vivo engineering and expansion of highly purified human hematopoietic stem and progenitor cell populations for gene therapy","volume":"8","author":"Zonari","year":"2017","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0480","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.ymthe.2017.05.023","article-title":"Improving gene therapy efficiency through the enrichment of human hematopoietic stem cells","volume":"25","author":"Masiuk","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0485","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1182\/blood-2010-02-271841","article-title":"Comparison of human cord blood engraftment between immunocompromised mouse strains","volume":"116","author":"McDermott","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0490","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1182\/blood-2009-10-249326","article-title":"Engraftment of human hematopoietic stem cells is more efficient in female NOD\/SCID\/IL-2Rgc-null recipients","volume":"115","author":"Notta","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0495","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nm1342","article-title":"Angiopoietin-like proteins stimulate ex vivo expansion of hematopoietic stem cells","volume":"12","author":"Zhang","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0500","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1182\/blood-2007-11-122119","article-title":"Angiopoietin-like 5 and IGFBP2 stimulate ex vivo expansion of human cord blood hematopoietic stem cells as assayed by NOD\/SCID transplantation","volume":"111","author":"Zhang","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0505","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1191536","article-title":"Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells","volume":"329","author":"Boitano","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0510","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nm.2080","article-title":"Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution","volume":"16","author":"Delaney","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0515","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1126\/science.1256337","article-title":"Cord blood expansion. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal","volume":"345","author":"Fares","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0520","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/nature05883","article-title":"Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis","volume":"447","author":"North","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0525","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.stem.2011.02.003","article-title":"Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models","volume":"8","author":"Goessling","year":"2011","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0530","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ymthe.2017.09.025","article-title":"Prostaglandin E2 increases lentiviral vector transduction efficiency of adult human hematopoietic stem and progenitor cells","volume":"26","author":"Heffner","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0535","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1182\/blood-2013-12-546218","article-title":"Rapamycin relieves lentiviral vector transduction resistance in human and mouse hematopoietic stem cells","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0540","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/mt.2014.193","article-title":"Cyclosporin a and rapamycin relieve distinct lentiviral restriction blocks in hematopoietic stem and progenitor cells","volume":"23","author":"Petrillo","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0545","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S1470-2045(08)70180-3","article-title":"Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I\/II study","volume":"9","author":"Frassoni","year":"2008","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0550","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1126\/science.288.5466.669","article-title":"Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease","volume":"288","author":"Cavazzana-Calvo","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0555","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jama.2015.3253","article-title":"Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome","volume":"313","author":"Hacein-Bey Abina","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0560","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1182\/blood-2017-04-777136","article-title":"Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult","volume":"130","author":"Morris","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0565","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","article-title":"Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial","volume":"388","author":"Sessa","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0570","series-title":"Changing the Face of Modern Medicine: Stem Cells and Gene Therapy, Human Gene Therapy, Florence, Italy","first-page":"A17","article-title":"A Phase I\/II clinical trial opened in September 2015 for X-linked chronic granulomatous diseases","author":"Kohn","year":"2016"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0575","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1182\/blood.V96.10.3624","article-title":"The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major","volume":"96","author":"Centis","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0580","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1089\/hum.2016.103","article-title":"The role of conditioning in hematopoietic stem cell gene therapy","volume":"27","author":"Bernardo","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0585","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nbt.3629","article-title":"Safer conditioning for blood stem cell transplants","volume":"34","author":"Aiuti","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0590","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.hoc.2017.06.003","article-title":"Opening marrow niches in patients undergoing autologous hematopoietic stem cell gene therapy","volume":"31","author":"Cowan","year":"2017","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0595","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1126\/science.1149726","article-title":"Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches","volume":"318","author":"Czechowicz","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0600","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1182\/blood-2010-07-295949","article-title":"Antibody targeting KIT as pretransplantation conditioning in immunocompetent mice","volume":"116","author":"Xue","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0605","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S0140-6736(09)60945-4","article-title":"Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1\/2 study","volume":"374","author":"Straathof","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0610","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nbt.3584","article-title":"Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin","volume":"34","author":"Palchaudhuri","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0615","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aae0501","article-title":"Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy","volume":"8","author":"Chhabra","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0620","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1182\/blood-2015-12-689083","article-title":"KIT blockade is sufficient for donor hematopoietic stem cell engraftment in Fanconi anemia mice","volume":"129","author":"Chandrakasan","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0625","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.bbmt.2011.11.003","article-title":"From biology to clinical practice: aging and hematopoietic cell transplantation","volume":"18","author":"Artz","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0630","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bbmt.2014.09.021","article-title":"Impact of donor age on outcome after allogeneic hematopoietic cell transplantation","volume":"21","author":"Rezvani","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0635","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood.V98.7.2043","article-title":"Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age","volume":"98","author":"Kollman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0640","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/nm0996-1011","article-title":"The aging of hematopoietic stem cells","volume":"2","author":"Morrison","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0645","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood.V93.10.3294.410k07_3294_3301","article-title":"Dynamic changes in mouse hematopoietic stem cell numbers during aging","volume":"93","author":"de Haan","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0650","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1084\/jem.156.6.1767","article-title":"Loss of stem cell repopulating ability upon transplantation. Effects of donor age, cell number, and transplantation procedure","volume":"156","author":"Harrison","year":"1982","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0655","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/ni0402-329","article-title":"The aging of lympho-hematopoietic stem cells","volume":"3","author":"Geiger","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0660","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/j.seminhematol.2016.10.001","article-title":"The aging hematopoietic stem cell niche: phenotypic and functional changes and mechanisms that contribute to hematopoietic aging","volume":"54","author":"Latchney","year":"2017","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0665","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/0092-8674(92)90030-G","article-title":"RAG-1-deficient mice have no mature B and T lymphocytes","volume":"68","author":"Mombaerts","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0670","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/0092-8674(92)90029-C","article-title":"RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement","volume":"68","author":"Shinkai","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0675","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0092-8674(01)00309-9","article-title":"Artemis, a novel DNA double-strand break repair\/V(D)J recombination protein, is mutated in human severe combined immune deficiency","volume":"105","author":"Moshous","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0680","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/ACI.0b013e3283327da5","article-title":"New insights into the pathogenesis of adenosine deaminase-severe combined immunodeficiency and progress in gene therapy","volume":"9","author":"Sauer","year":"2009","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0685","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1182\/blood-2011-01-329359","article-title":"Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency","volume":"118","author":"Sokolic","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0690","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2016-01-688226","article-title":"Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"128","author":"Cicalese","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0695","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1182\/blood-2002-07-2099","article-title":"A defect in hematopoietic stem cell migration explains the nonrandom X-chromosome inactivation in carriers of Wiskott-Aldrich syndrome","volume":"102","author":"Lacout","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0700","doi-asserted-by":"crossref","first-page":"8153","DOI":"10.1038\/s41598-017-08550-5","article-title":"Biological and functional characterization of bone marrow-derived mesenchymal stromal cells from patients affected by primary immunodeficiency","volume":"7","author":"Starc","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0705","series-title":"Changing the Face of Modern Medicine: Stem Cells and Gene Therapy, Human Gene Therapy. Nov 2016","first-page":"A38","article-title":"Thalassemic bone marrow microenvironment accelerates hematopoietic stem cell ageing and exhaustion","author":"Aprile","year":"2016"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0710","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-2141.1975.tb00869.x","article-title":"Ultrastructural studies of the bone marrow in sickle cell anaemia. II. The morphology of erythropoietic cells and their response to deoxygenation in vitro","volume":"31","author":"Grasso","year":"1975","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0715","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1365-2141.1975.tb00844.x","article-title":"Ultrastructural studies of the bone marrow in sickle cell anaemia. I. The structure of sickled erythrocytes and reticulocytes and their phagocytic destruction","volume":"31","author":"Grasso","year":"1975","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0720","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/MOH.0000000000000241","article-title":"New insights into sickle cell disease: mechanisms and investigational therapies","volume":"23","author":"Kato","year":"2016","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0725","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010853","article-title":"Erythropoietin couples hematopoiesis with bone formation","volume":"5","author":"Shiozawa","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0730","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1517\/13543784.14.3.251","article-title":"Parathyroid hormone and leptin\u2014new peptides, expanding clinical prospects","volume":"14","author":"Whitfield","year":"2005","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0735","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10517-006-0408-5","article-title":"Stromal regulation of hemopoietic stem cells in long-term human bone marrow tissue cultures under the effect of parathyroid hormone","volume":"142","author":"Petrova","year":"2006","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0740","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/nature02040","article-title":"Osteoblastic cells regulate the haematopoietic stem cell niche","volume":"425","author":"Calvi","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0745","series-title":"Iron Metabolism: From Molecular Mechanisms to Clinical Consequences","author":"Crichton","year":"2009"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0750","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1089\/ars.2014.5941","article-title":"Reactive oxygen species regulate hematopoietic stem cell self-renewal, migration and development, as well as their bone marrow microenvironment","volume":"21","author":"Ludin","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0755","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.cell.2008.10.048","article-title":"Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair","volume":"135","author":"Wilson","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0760","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1196\/annals.1422.035","article-title":"Regulation of cytokine-induced HIF-1alpha expression in rheumatoid synovial fibroblasts","volume":"1108","author":"Westra","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0765","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2009-09-241000","article-title":"AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species","volume":"115","author":"Juntilla","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0770","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm1388","article-title":"Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells","volume":"12","author":"Ito","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0775","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1182\/blood-2007-05-087759","article-title":"A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche","volume":"110","author":"Jang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0780","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/nature02989","article-title":"Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells","volume":"431","author":"Ito","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0785","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/ejh.12309","article-title":"The bone marrow hematopoietic microenvironment is impaired in iron-overloaded mice","volume":"93","author":"Okabe","year":"2014","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0790","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nm.4313","article-title":"Refining strategies to translate genome editing to the clinic","volume":"23","author":"Cornu","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0795","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0800","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nmeth.1653","article-title":"High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases","volume":"8","author":"Chen","year":"2011","journal-title":"Nat. Methods"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0805","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/gt.2010.65","article-title":"Self-complementary AAV mediates gene targeting and enhances endonuclease delivery for double-strand break repair","volume":"17","author":"Hirsch","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0810","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.cell.2014.05.050","article-title":"Reactivation of developmentally silenced globin genes by forced chromatin looping","volume":"158","author":"Deng","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0815","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/bit.25018","article-title":"Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs","volume":"111","author":"Sun","year":"2014","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0820","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1182\/blood-2014-12-615948","article-title":"Correction of the sickle cell disease mutation in human hematopoietic stem\/progenitor cells","volume":"125","author":"Hoban","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0825","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/mt.2016.148","article-title":"CRISPR\/Cas9-mediated correction of the sickle mutation in human CD34+ cells","volume":"24","author":"Hoban","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0830","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nbt1176","article-title":"A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference","volume":"24","author":"Samakoglu","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0835","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00277-012-1430-5","article-title":"A combined approach for beta-thalassemia based on gene therapy-mediated adult hemoglobin (HbA) production and fetal hemoglobin (HbF) induction","volume":"91","author":"Zuccato","year":"2012","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0840","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1182\/blood-2012-06-292078","article-title":"Reawakening fetal hemoglobin: prospects for new therapies for the beta-globin disorders","volume":"120","author":"Bauer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0845","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nbt.2136","article-title":"Massively parallel functional dissection of mammalian enhancers in vivo","volume":"30","author":"Patwardhan","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0850","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.2137","article-title":"Systematic dissection and optimization of inducible enhancers in human cells using a massively parallel reporter assay","volume":"30","author":"Melnikov","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0855","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrg2554","article-title":"Human genetic variation and its contribution to complex traits","volume":"10","author":"Frazer","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0860","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1126\/science.1242088","article-title":"An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level","volume":"342","author":"Bauer","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0865","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nature15521","article-title":"BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis","volume":"527","author":"Canver","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0870","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/nmeth.3554","article-title":"Functional footprinting of regulatory DNA","volume":"12","author":"Vierstra","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0875","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1016\/j.celrep.2016.08.064","article-title":"Bcl11a deficiency leads to hematopoietic stem cell defects with an aging-like phenotype","volume":"16","author":"Luc","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0880","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1172\/JCI87885","article-title":"Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype","volume":"126","author":"Brendel","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0885","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.omtm.2016.12.009","article-title":"Long-term engraftment and fetal globin induction upon BCL11A gene editing in bone-marrow-derived CD34+ hematopoietic stem and progenitor cells","volume":"4","author":"Chang","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0890","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf9336","article-title":"Selection-free genome editing of the sickle mutation in human adult hematopoietic stem\/progenitor cells","volume":"8","author":"DeWitt","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0895","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature13420","article-title":"Targeted genome editing in human repopulating haematopoietic stem cells","volume":"510","author":"Genovese","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0900","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature20134","article-title":"CRISPR\/Cas9 beta-globin gene targeting in human haematopoietic stem cells","volume":"539","author":"Dever","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2017.12.001_bb0905","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1038\/ncomms8085","article-title":"Editing the genome to introduce a beneficial naturally occurring mutation associated with increased fetal globin","volume":"6","author":"Wienert","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0910","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm.4170","article-title":"A genome-editing strategy to treat beta-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition","volume":"22","author":"Traxler","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0915","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nbt.2623","article-title":"High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells","volume":"31","author":"Fu","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0920","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nbt.3101","article-title":"Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases","volume":"33","author":"Frock","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0925","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/nbt.1948","article-title":"An unbiased genome-wide analysis of zinc-finger nuclease specificity","volume":"29","author":"Gabriel","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0930","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nbt.3117","article-title":"GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases","volume":"33","author":"Tsai","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0935","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/B978-0-12-801185-0.00003-9","article-title":"Determining the specificities of TALENs, Cas9, and other genome-editing enzymes","volume":"546","author":"Pattanayak","year":"2014","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.bcmd.2017.12.001_bb0940","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41467-017-00479-7","article-title":"Editing an alpha-globin enhancer in primary human hematopoietic stem cells as a treatment for beta-thalassemia","volume":"8","author":"Mettananda","year":"2017","journal-title":"Nat. Commun."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979617304291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979617304291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:35:09Z","timestamp":1761050109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979617304291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":187,"alternative-id":["S1079979617304291"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2017.12.001","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy and gene editing strategies for hemoglobinopathies","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2017.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}